An interventional study of Livi Postcoital Tampon Device in Vaginal Discharge and Postcoital Vaginal Changes, sponsored by Atlantic Health System. Completed at 1 site in United States. Open to female participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-04.
Sponsored by Atlantic Health System · Not applicable, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Vaginal Discharge with a site in United States — 1 open to participants now, 1 under way, none of them phase 3. Vaginal Discharge · United States.
Among the 10 studies in Vaginal Discharge with a site in United States, this one is the 7th largest by enrollment, is the only one that started in 2026, is one of 7 with no phase, and was the 9th registered.
21 studies on the registry are indexed under Vaginal Discharge; 2 are open to participants now.
Browse Vaginal Discharge studies →1 of the 10 studies in Vaginal Discharge with a site in United States is open now. Recruiting first, the newest first:
Atlantic Health System · Sites in United States
Ages 18+ · Women only · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 1 Vaginal Discharge study recruiting now, 1 sets no upper age limit and none stop at 75 or younger; none take children under 18; 1 takes healthy volunteers.
This study: 18 Years and older · female · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2010; this study’s year is marked. 1 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 60 is below the median of 127 across 16 interventional studies indexed under Vaginal Discharge.
Median enrollment 91 across the 10 interventional studies. Of the 8 that completed or were terminated, 3 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 10 have an industry lead sponsor. The 8 most frequent:
Atlantic Health System is the lead sponsor of 64 studies on the registry; 12 are open to participants now.
Atlantic Health System has 3 studies filed under Vaginal Discharge — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 10 studies in Vaginal Discharge with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to learn if the Livi postcoital tampon device is safe for repetitive use in sexually active women aged 18 years and older. The main question it aims to answer is:
Does using the Livi device three times in a row cause any visible vaginal mucosal trauma? How much pain or discomfort do participants experience during insertion and removal?
Researchers will not compare the Livi device to another product because this is a single-arm safety study.
Participants will:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will insert and remove the Livi device three times consecutively during a single clinic visit.
Device: Livi Postcoital Tampon Device
Single-use polyurethane foam pledget inserted via disposable applicator, designed to absorb semen post-intercourse.
Incidence of Grade ≥2 vaginal mucosal trauma
Incidence of Grade ≥2 vaginal mucosal trauma assessed immediately after device removal via digital colposcopic examination. Mucosal trauma defined as: Grade 2 (Moderate): Abrasion \>5 mm or multiple foci totaling \>10 mm; pinpoint bleeding stopping spontaneously. Grade 3 (Severe): Laceration or bleeding requiring medical intervention.
Time frame: Immediate post-use (within 5 minutes of device removal)
Pain/discomfort during insertion/removal
Immediately after device insertion and removal, Numeric Rating Scale (0- no pain to 10- maximum pain) will be self-reported by patient.
Time frame: During Visit 1, immediately after device insertion/removal, and at 24-hours (+/- 6 hr)
Ease of use
Likert scale on ease of overall device use - Very Easy, Easy, Neither Easy Nor Difficult, Difficult, Very Difficult
Time frame: During Visit 1 immediately following third device insertion
Spotting or pain within 24 hours post-use
self-reported by subject on e-diary or telephone survey
Time frame: 24-hour (+/- 6hr) follow-up
Allergy and Hypersensitivity Responses
Mucosal changes consistent with allergy or hypersensitivity (eg edema, urticaria, swelling, itching) will be documented - this will be both reported subjectively by the patient, and objectively reported by the clinician using digital colposcopy examinations.
Time frame: after each study device removal, and up to 7 days following visit 1
Plan to share: Undecided
No publications or documents are linked to this record.
Ran from Jan 2026 to primary completion in Feb 2026, 0 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Atlantic Health System